Reviva Pharmaceuticals (NASDAQ:RVPH) Coverage Initiated by Analysts at Roth Mkm

Roth Mkm assumed coverage on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a research report released on Friday morning,Benzinga reports. The brokerage issued a buy rating and a $7.00 target price on the stock.

Separately, EF Hutton Acquisition Co. I raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 23rd. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $11.25.

Reviva Pharmaceuticals Price Performance

Shares of Reviva Pharmaceuticals stock opened at $1.88 on Friday. The stock’s 50-day moving average is $1.56 and its 200 day moving average is $1.29. Reviva Pharmaceuticals has a one year low of $0.60 and a one year high of $4.83. The firm has a market cap of $62.87 million, a price-to-earnings ratio of -1.69 and a beta of -0.12.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC grew its position in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 278,496 shares of the company’s stock after acquiring an additional 42,376 shares during the quarter. Geode Capital Management LLC owned about 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent filing with the Securities & Exchange Commission. 63.18% of the stock is owned by institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.